Displaying 1 - 10 of 14 for Cancer - Leukemia
  • Acute Myeloid Leukemia Study (H-41506)
    • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo.
  • ADSPAM Study (H-36346)
    • The purpose of this study is to find the largest safe dose of donor-derived tumor protein multi-TAA-specific T cells for patients with AML or MDS.
  • CARPASCIO Study (H-33133)
    • The purpose of this study is to see whether this therapy might help people with lymphoma or leukemia after a stem cell transplantation from a donor.
  • CHARKALL Study (H-23574)
    • Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL. The lymphoma, MM or CLL has come back or has not gone away after treatment. This is a gene transfer research study using special immune cells.
  • MAGENTA Study (H-40466)
    • This research study combines antibodies and T cells to fight a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer).
  • MOHEL Study (H-8701)
    • Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
  • PREVALE Study (H-39090)
    • The purpose of this study is to find out if LMP-specific EB-VST cells in combination with nivolumab are safe, to learn what the side effects are, and to see whether this therapy may help patients with EBV related lymphoma or LPD.
  • Prevention of Graft-versus-Host Disease Study (H-36264)
    • The purpose of this study is to compare calcineurin inhibitor (CNI)-free strategies for graft-versus-host disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies.
  • Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (H-38468)
    • The purpose of this study is to determine the safety and efficacy of KTE-C19 in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.
  • REMAIN Study (H-40203)
    • This trial studies how well nivolumab works in eliminating any remaining cancer cells and preventing cancer from returning in patients with acute myeloid leukemia who had a decrease in or disappearance of signs of cancer after receiving chemotherapy.